OPKO HEALTH, INC. Amends Filing for GeneDx Holdings Corp.
Ticker: OPK · Form: SC 13D/A · Filed: Aug 12, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | SC 13D/A |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $29.00, $34.90, $10,262,858, $26.4607 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, ownership-change, amendment
TL;DR
OPKO HEALTH, INC. just filed an update on their stake in GeneDx Holdings Corp. - check it out!
AI Summary
On August 12, 2024, OPKO HEALTH, INC. filed an SC 13D/A amendment regarding GeneDx Holdings Corp. The filing indicates a change in beneficial ownership, with OPKO HEALTH, INC. now holding a significant stake in GeneDx Holdings Corp. This amendment updates the previous filing concerning their holdings.
Why It Matters
This filing signals a potential shift in control or influence over GeneDx Holdings Corp. by OPKO HEALTH, INC., which could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can indicate significant strategic moves by companies, potentially leading to volatility.
Key Players & Entities
- OPKO HEALTH, INC. (company) — Filing entity
- GeneDx Holdings Corp. (company) — Subject company
- Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
- CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.
- Opko Health, Inc. (company) — Former name of OPKO HEALTH, INC.
- eXegenics Inc (company) — Former name of OPKO HEALTH, INC.
FAQ
What specific changes in beneficial ownership are detailed in this SC 13D/A filing for OPKO HEALTH, INC. regarding GeneDx Holdings Corp.?
The filing is an amendment to a previous Schedule 13D, indicating a change in beneficial ownership. Specific details on the exact percentage or number of shares acquired or disposed of are not present in the provided header information, but the filing type itself signifies a material change.
When was this SC 13D/A filing submitted to the SEC?
The filing was submitted on August 12, 2024.
What is the primary business of GeneDx Holdings Corp.?
GeneDx Holdings Corp. is in the Services-Health Services industry, as indicated by its SIC code 8000.
What is the primary business of OPKO HEALTH, INC.?
OPKO HEALTH, INC. is in the Pharmaceutical Preparations industry, with a SIC code of 2834.
Has GeneDx Holdings Corp. undergone name changes prior to this filing?
Yes, GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp. (name change on 20210721) and CM Life Sciences, Inc. (name change on 20200715).
Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 7.8 · Accepted 2024-08-12 18:27:05
Key Financial Figures
- $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
- $29.00 — the open market at prices ranging from $29.00 to $34.90 per share for an aggregate sa
- $34.90 — market at prices ranging from $29.00 to $34.90 per share for an aggregate sale price o
- $10,262,858 — n aggregate sale price of approximately $10,262,858. ITEM 5. Interest in Securities of
- $26.4607 — the open market at prices ranging from $26.4607 to $34.90 per share for an aggregate sa
- $24,070,642 — n aggregate sale price of approximately $24,070,642. Sales of GeneDx Common Stock prior to
Filing Documents
- opk20240808_sc13da.htm (SC 13D/A) — 71KB
- 0001437749-24-026120.txt ( ) — 73KB
is amended by adding the following paragraph to the end of the item
Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between July 29, 2024 and August 12, 2024, OPKO sold a total of 311,620 shares of GeneDx Common Stock on the open market at prices ranging from $29.00 to $34.90 per share for an aggregate sale price of approximately $10,262,858. ITEM 5. Interest in Securities of the Issuer.
is deleted in its entirety and replaced with the following text
Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 2,811,783 10.44% ______________ (1) Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on July 30, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 5, OPKO sold a total of 746,820 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $34.90 per share for an aggregate sale price of approximately $24,070,642. Sales of GeneDx Common Stock prior to July 29, 2024 were previously reported in Amendment No. 4. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Price Per Share 7/1/24 50,000 $ 1,331,669 $ 26.6340 7/2/24 25,000 $ 728,095 $ 29.1238 7/3/24 14,082 $ 397,491 $ 28.2269 7/5/24 36,118 $ 1,020,015 $ 28.2412 7/17/24 25,000 $ 823,187 $ 32.9275 7/19/24 25,000 $ 807,250 $ 32.29 7/22/24 50,000 $ 1,630,422 $ 32.6088 7/23/24 75,000 $ 2,509,248 $ 33.4566 7/24/24 75,000 $ 2,529,102 $ 33.7214 7/26/24 60,000 $ 2,031,255 $ 33.8543 7/29/24 50,000 $ 1,692,890 $ 33.8578 7/31/24 88,839 $ 2,976,350 $ 33.5027 8/6/24 12,994 $ 381,427 $ 29.3541 8/8/24 100,000 $ 3.182.380 $ 31.8238 8/12/24 59,787 $ 2,029,811 $ 33.9507 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 (d) Except as described herein, n
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: August 12, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration